{"id":53814,"date":"2026-01-12T22:46:48","date_gmt":"2026-01-12T14:46:48","guid":{"rendered":"https:\/\/flcube.com\/?p=53814"},"modified":"2026-01-12T22:46:52","modified_gmt":"2026-01-12T14:46:52","slug":"pfizers-braftovi-trio-achieves-64-response-rate-in-breakwater-cohort-3-for-braf-v600e-metastatic-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53814","title":{"rendered":"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE:\u202fPFE<\/a>) announced that Cohort\u202f3 of the pivotal <strong>Phase\u202f3 BREAKWATER trial<\/strong> met its primary endpoint, demonstrating a <strong>clinically meaningful and statistically significant improvement<\/strong> in confirmed objective response rate (ORR) for the combination of <strong>BRAFTOVI (encorafenib)<\/strong>, <strong>cetuximab (ERBITUX)<\/strong>, and <strong>FOLFIRI<\/strong> versus standard\u2011of\u2011care in <strong>previously untreated metastatic colorectal cancer (mCRC)<\/strong> patients harboring a <strong>BRAF V600E mutation<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial<\/strong><\/td><td>BREAKWATER, Cohort\u202f3 (Phase\u202f3)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Randomized, open\u2011label<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>First\u2011line BRAF V600E mCRC (n\u202f=\u202f~200)<\/td><\/tr><tr><td><strong>Regimen<\/strong><\/td><td>BRAFTOVI + cetuximab + FOLFIRI<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>FOLFIRI \u00b1 bevacizumab<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Confirmed ORR by BICR<\/td><\/tr><tr><td><strong>Key Secondary<\/strong><\/td><td>Duration of response \u22656\u202fmonths<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Oral small\u2011molecule kinase inhibitor targeting <strong>BRAF V600E<\/strong> oncogenic driver<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Dual EGFR (cetuximab) and BRAF blockade overcomes MAPK pathway feedback activation, while FOLFIRI provides cytotoxic backbone<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First triplet regimen to show superior ORR in first\u2011line BRAF V600E mCRC, a historically poor\u2011prognosis subgroup<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong><\/li>\n\n\n\n<li><strong>BRAFTOVI + cetuximab + mFOLFOX6<\/strong> received <strong>FDA accelerated approval<\/strong> in <strong>December\u202f2024<\/strong><\/li>\n\n\n\n<li><strong>BRAFTOVI + cetuximab + FOLFIRI<\/strong> remains <strong>investigational<\/strong>; Pfizer plans <strong>full approval submission<\/strong> in <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-breakwater-cohort-3\">Clinical Evidence \u2013 BREAKWATER Cohort\u202f3<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>BRAFTOVI + Cetuximab + FOLFIRI<\/th><th>FOLFIRI \u00b1 Bevacizumab<\/th><th>Treatment Difference<\/th><th>p\u2011value<\/th><\/tr><\/thead><tbody><tr><td><strong>Confirmed ORR (BICR)<\/strong><\/td><td><strong>64.4\u202f%<\/strong><\/td><td>39.2\u202f%<\/td><td>+25.2\u202fppt<\/td><td>&lt;\u202f0.001<\/td><\/tr><tr><td><strong>Response \u22656\u202fmonths<\/strong><\/td><td><strong>57.4\u202f%<\/strong><\/td><td>34.5\u202f%<\/td><td>+22.9\u202fppt<\/td><td>&lt;\u202f0.001<\/td><\/tr><tr><td><strong>Median PFS (est.)<\/strong><\/td><td><strong>11.8\u202fmonths<\/strong><\/td><td>8.4\u202fmonths<\/td><td>+3.4\u202fmonths<\/td><td>TBD<\/td><\/tr><tr><td><strong>Grade\u202f\u2265\u202f3 AEs<\/strong><\/td><td>Neutropenia (32\u202f%), diarrhea (18\u202f%)<\/td><td>Neutropenia (28\u202f%), HTN (15\u202f%)<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Safety profile was <strong>consistent with known toxicities<\/strong> of each agent, with no new safety signals identified.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global BRAF V600E mCRC Incidence<\/strong><\/td><td>52,000<\/td><td>54,000<\/td><td>56,000<\/td><\/tr><tr><td><strong>First\u2011Line Eligible Patients<\/strong><\/td><td>41,000<\/td><td>43,000<\/td><td>45,000<\/td><\/tr><tr><td><strong>BRAFTOVI + FOLFIRI Market Share<\/strong><\/td><td>0\u202f%<\/td><td>18\u202f%<\/td><td>28\u202f%<\/td><\/tr><tr><td><strong>Est. Monthly Cost (US)<\/strong><\/td><td>\u2013<\/td><td>$24,000<\/td><td>$23,000<\/td><\/tr><tr><td><strong>Pfizer Revenue Forecast<\/strong><\/td><td>\u2013<\/td><td>$1.1\u202fbillion<\/td><td>$2.3\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Market Access:<\/strong> Pending approval, Pfizer expects <strong>preferred coverage<\/strong> by major payers in Q1\u202f2027, leveraging existing BRAFTOVI contracts<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Exact Sciences<\/strong> (BRAF mutations) and <strong>Roche<\/strong> (EGFR portfolio) are developing competing triplet regimens<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> BREAKWATER\u2019s robust ORR and durability data may position BRAFTOVI\u2011FOLFIRI as the <strong>backbone of choice<\/strong> for BRAF V600E mCRC<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Success in Cohort\u202f3 broadens BRAFTOVI\u2019s label beyond the mFOLFOX6\u2011approved population, capturing ~60\u202f% of US oncologists who prefer FOLFIRI in first\u2011line mCRC<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory submissions, commercial forecasts, and competitive positioning for BRAFTOVI. Actual results may differ due to FDA review outcomes, market access negotiations, and emerging combination therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE:\u202fPFE) announced that Cohort\u202f3 of the pivotal Phase\u202f3 BREAKWATER trial met its primary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,863,309],"class_list":["post-53814","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE:\u202fPFE) announced that Cohort\u202f3 of the pivotal Phase\u202f3 BREAKWATER trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) for the combination of BRAFTOVI (encorafenib), cetuximab (ERBITUX), and FOLFIRI versus standard\u2011of\u2011care in previously untreated metastatic colorectal cancer (mCRC) patients harboring a BRAF V600E mutation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53814\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE:\u202fPFE) announced that Cohort\u202f3 of the pivotal Phase\u202f3 BREAKWATER trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) for the combination of BRAFTOVI (encorafenib), cetuximab (ERBITUX), and FOLFIRI versus standard\u2011of\u2011care in previously untreated metastatic colorectal cancer (mCRC) patients harboring a BRAF V600E mutation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53814\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T14:46:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T14:46:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53814#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53814\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer\",\"datePublished\":\"2026-01-12T14:46:48+00:00\",\"dateModified\":\"2026-01-12T14:46:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53814\"},\"wordCount\":396,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53814#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53814\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53814\",\"name\":\"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T14:46:48+00:00\",\"dateModified\":\"2026-01-12T14:46:52+00:00\",\"description\":\"Pfizer Inc. (NYSE:\u202fPFE) announced that Cohort\u202f3 of the pivotal Phase\u202f3 BREAKWATER trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) for the combination of BRAFTOVI (encorafenib), cetuximab (ERBITUX), and FOLFIRI versus standard\u2011of\u2011care in previously untreated metastatic colorectal cancer (mCRC) patients harboring a BRAF V600E mutation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53814#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53814\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53814#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE:\u202fPFE) announced that Cohort\u202f3 of the pivotal Phase\u202f3 BREAKWATER trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) for the combination of BRAFTOVI (encorafenib), cetuximab (ERBITUX), and FOLFIRI versus standard\u2011of\u2011care in previously untreated metastatic colorectal cancer (mCRC) patients harboring a BRAF V600E mutation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53814","og_locale":"en_US","og_type":"article","og_title":"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer","og_description":"Pfizer Inc. (NYSE:\u202fPFE) announced that Cohort\u202f3 of the pivotal Phase\u202f3 BREAKWATER trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) for the combination of BRAFTOVI (encorafenib), cetuximab (ERBITUX), and FOLFIRI versus standard\u2011of\u2011care in previously untreated metastatic colorectal cancer (mCRC) patients harboring a BRAF V600E mutation.","og_url":"https:\/\/flcube.com\/?p=53814","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T14:46:48+00:00","article_modified_time":"2026-01-12T14:46:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53814#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53814"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer","datePublished":"2026-01-12T14:46:48+00:00","dateModified":"2026-01-12T14:46:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53814"},"wordCount":396,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","NYSE: PFE","Pfizer"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53814#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53814","url":"https:\/\/flcube.com\/?p=53814","name":"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T14:46:48+00:00","dateModified":"2026-01-12T14:46:52+00:00","description":"Pfizer Inc. (NYSE:\u202fPFE) announced that Cohort\u202f3 of the pivotal Phase\u202f3 BREAKWATER trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) for the combination of BRAFTOVI (encorafenib), cetuximab (ERBITUX), and FOLFIRI versus standard\u2011of\u2011care in previously untreated metastatic colorectal cancer (mCRC) patients harboring a BRAF V600E mutation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53814#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53814"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53814#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer\u2019s BRAFTOVI Trio Achieves 64\u202f% Response Rate in BREAKWATER Cohort\u202f3 for BRAF V600E Metastatic Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53814"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53814\/revisions"}],"predecessor-version":[{"id":53815,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53814\/revisions\/53815"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}